Carcell Biopharma Inc. is an EVX company that develops next generation cell and gene therapies. Based in both Singapore & Shanghai, Carcell is co-founded by industry veterans with work experience across China, Singapore and Boston. Carcell is establishing an integrated R&D and manufacturing center in Shanghai Waigaoqiao, and also has a top-notch R&D team in Singapore. Carcell's two lead platforms are around engineered red blood cells for immuno-modulation, and non-viral gene delivery using lipid nanoparticles.
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | EVX Ventur... | evx.ventur... |
Mentions in press and media 2
| Date | Title | Description |
| 19.12.2022 | Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board | SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He joins Prof. Jianzhu Chen of... |
| 02.11.2021 | Carcell Biopharma closes an oversubscribed financing round led by Hyfinity Investments | SINGAPORE, Nov. 2, 2021 /PRNewswire/ -- Carcell Biopharma ("Carcell", the "Company") announced today the close of an over-subscribed financing. The round was led by Hyfinity Investments, with participation from BioTrack ... |